Hebang Bio's H1 2026 Net Profit Rises 634.3% to RMB 380 Million
Hebang Bio reported a 634.3% year-on-year increase in net profit attributable to shareholders to RMB 380 million for the first half of 2026, despite a 26.34% decline in revenue to RMB 2.888 billion. Basic earnings per share were RMB 0.0471. The company attributed the profit growth to higher market prices for its main products: glyphosate intermediate, glyphosate, and methionine.
Hebang Bio released its semi-annual report for 2026. During the reporting period, the company recorded revenue of RMB 2.888 billion, down 26.34% year on year, while net profit attributable to shareholders of the listed company reached RMB 380 million, up 634.3% year on year. Basic earnings per share were RMB 0.0471.
The company said that rising market prices for its main products — glyphosate intermediate, glyphosate, and methionine — drove the overall profit growth.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Agrochemicals & Fertilizers, with intensity 60/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.